Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, Melt-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
Melt Pharmaceuticals宣佈，其領先的產品候選者Melt-300的關鍵3期計劃的第一名患者在接受白內障手術的患者中進行了無針和無阿片類鎮靜治療。